Characterization of substrate binding to cytochrome P450 1A1 using molecular modeling and kinetic analyses: Case of residue 382

被引:48
作者
Liu, JG
Ericksen, SS
Besspiata, D
Fisher, CW
Szklarz, GD
机构
[1] W Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA
[2] Texas Tech Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Amarillo, TX USA
关键词
D O I
10.1124/dmd.31.4.412
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Key residue Val-382 in P450 1A1 has been predicted to interact with the alkoxy chain of resorufin derivatives. Therefore, we undertook a detailed analysis of substrate mobility in the active site of the P450 1A1 homology model and assessed the effect of mutations at position 382. Dynamic trajectories of 7-methoxy-, 7-ethoxy-, and 7-pentoxyresorufin indicated that 7-ethoxyresorufin would be oxidized most efficiently by the wild-type enzyme. The Val-382-->Ala mutation would increase the O-dealkylation of 7-pentoxyresorufin but decrease the oxidation of other substrates. In the case of the V382L mutant, the large bulk of Leu would block alkoxyresorufins from productive binding orientations leading to lowered activities. Binding free energy calculations for three substrates with 1A1 WT and two mutants indicated that binding constants would be similar,for all enzyme-substrate combinations. Modeling predictions were tested experimentally. The plasmid containing the cDNA for human P450 1A1 modified for bacterial expression was altered to include a C-terminal PCR-generated six histidine domain to facilitate enzyme purification. The V382A and V382L mutants were constructed by site-directed mutagenesis and Escherichia coli-expressed enzymes purified using Ni-NTA affinity chromatography. The activity of the WT 1A1 was highest toward 7-ethoxyresorufin and lowest toward 7-pentoxyresorufin. Both mutants displayed a decrease in V-max with 7-methoxy- and 7-ethoxyresorufin, whereas for the V382A mutant, V-max with 7-pentoxyresorufin was increased. No significant changes in K-m were observed relative to the wild-type enzyme. The experimental results are thus in good agreement with modeling predictions.
引用
收藏
页码:412 / 420
页数:9
相关论文
共 38 条
[1]   CYTOCHROME-P450 SPECIFICITIES OF ALKOXYRESORUFIN O-DEALKYLATION IN HUMAN AND RAT-LIVER [J].
BURKE, MD ;
THOMPSON, S ;
WEAVER, RJ ;
WOLF, CR ;
MAYER, RT .
BIOCHEMICAL PHARMACOLOGY, 1994, 48 (05) :923-936
[2]  
BURKE MD, 1983, CHEM-BIOL INTERACT, V45, P243
[3]   Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis [J].
Domanski, TL ;
Halpert, JR .
CURRENT DRUG METABOLISM, 2001, 2 (02) :117-137
[4]   HIGH-LEVEL EXPRESSION OF FUNCTIONAL HUMAN CYTOCHROME-P450 1A2 IN ESCHERICHIA-COLI [J].
FISHER, CW ;
CAUDLE, DL ;
MARTINWIXTROM, C ;
QUATTROCHI, LC ;
TUKEY, RH ;
WATERMAN, MR ;
ESTABROOK, RW .
FASEB JOURNAL, 1992, 6 (02) :759-764
[5]  
Guengerich FP, 1995, CYTOCHROME P, P473
[6]   EXPRESSION OF MODIFIED HUMAN CYTOCHROME-P450-1A1 IN ESCHERICHIA-COLI - EFFECTS OF 5' SUBSTITUTION, STABILIZATION, PURIFICATION, SPECTRAL CHARACTERIZATION, AND CATALYTIC PROPERTIES [J].
GUO, ZY ;
GILLAM, EMJ ;
OHMORI, S ;
TUKEY, RH ;
GUENGERICH, FP .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1994, 312 (02) :436-446
[7]   Metabolism of carcinogenic heterocyclic and aromatic amines by recombinant human cytochrome P450 enzymes [J].
Hammons, GJ ;
Milton, D ;
Stepps, K ;
Guengerich, FP ;
Tukey, RH ;
Kadlubar, FF .
CARCINOGENESIS, 1997, 18 (04) :851-854
[8]   Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4 - Role of residues 210 and 211 in flavonoid activation and substrate specificity [J].
Harlow, GR ;
Halpert, JR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (09) :5396-5402
[9]   Interconversion of the androstenedione hydroxylase specificities of cytochromes p450 2B4 and 2B5 upon simultaneous site-directed mutagenesis of four key substrate recognition residues [J].
He, YQ ;
Szklarz, GD ;
Halpert, JR .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1996, 335 (01) :152-160
[10]   CYP1A1 polymorphisms and lung cancer risk:: a meta-analysis [J].
Houlston, RS .
PHARMACOGENETICS, 2000, 10 (02) :105-114